GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Total Receivables

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Total Receivables : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Total Receivables?

Clarity Pharmaceuticals's Total Receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.


Clarity Pharmaceuticals Total Receivables Historical Data

The historical data trend for Clarity Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Total Receivables Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Total Receivables
4.68 6.71

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial 0.18 4.68 - 6.71 -

Clarity Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Clarity Pharmaceuticals Total Receivables Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.